<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OPC-14005546</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2014-11-24</date_registration>
      <primary_sponsor>Peking University People's Hospital</primary_sponsor>
      <public_title>Clincal study of interferon-alpha for prevention of relapse after transplantation in Ph+ALL patients with CD34+CD38-CD58- phenotype at diagnosis</public_title>
      <acronym />
      <scientific_title>Clincal study of interferon-alpha for prevention of relapse after transplantation in Ph+ALL patients with CD34+CD38-CD58- phenotype at diagnosis</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2014-11-20</date_enrolment>
      <type_enrolment />
      <target_size>case series:15;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=9917</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>I (Phase I study)</phase>
      <hc_freetext>acute lymphoblastic leukemia</hc_freetext>
      <i_freetext>case series:IFN-alpha ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>SUN YU-QIAN</firstname>
        <middlename />
        <lastname />
        <address>NO.11, South Xizhimen street, Xicheng district, Beijing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 010-88324670</telephone>
        <email>sunyuqian83@163.com</email>
        <affiliation>Peking University People's Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>HUANG XIAO-JUN</firstname>
        <middlename />
        <lastname />
        <address>NO.11, South Xizhimen street, Xicheng district, Beijing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 010-88324577</telephone>
        <email>sunyuqian83@163.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Ph positive ALL in CR1/CR2 and received allo-HSCT;
2. with CD34+CD38-CD58- phenotype at diagnosis;
3. in CR at 4.5 months after HSCT;
4. adults (14-60);
5. with written informed consent.</inclusion_criteria>
      <agemin>14</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. active GVHD;
2. myelosuppression: WBC less than 2*10^9/L, ANC less than 1*10^9/L, PLT less than 50*10^9/L, HB less than 65g/L;
3. severe infection;
4. organ failure;
5. with prior history of DLI;
6. refuse to receive.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>toxicity;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self supported</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-09-23</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>